Every material Form 8-K Tevogen Inc. has filed with the SEC since September 30, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Tevogen Inc. disclosed that director Susan Podlogar resigned from the board effective immediately on November 2, 2026. The board reduced its size from six to five directors and named current director Lindee Goh to the Audit Committee, both effective the same day.
Susan Podlogar resigned as a director effective November 2, 2026, with notice given that day
Board size reduced from six directors to five
Lindee Goh, an existing director, appointed to the Audit Committee effective November 2, 2026
Tevogen amended its loan agreement with The Patel Family, LLP, extending the borrowing window to May 31, 2029 and fixing a $7.40 per-share price for share-based repayments. On November 2, 2026, the company repaid the entire $7.4 million principal balance and $177,880 of accrued interest by issuing 1,000,000 principal shares and 23,733 interest shares, eliminating all loan liabilities. The filing also grants CEO Ryan Saadi a 50,000,000-share restricted award that vests only if Tevogen reaches $1.0 billion in aggregate revenue by December 31, 2031.
Loan amended October 27, 2026; borrowing window extended from May 31, 2027 to May 31, 2029; up to $28.6 million remaining available
November 2, 2026: $7.4 million principal and $177,880 interest repaid in 1,000,000 principal shares and 23,733 interest shares
CEO Ryan Saadi granted 50,000,000 restricted shares, vesting only if $1.0 billion aggregate revenue is certified by December 31, 2031
Filing states Saadi held approximately 90.9% of voting power after the grant and repayment
Tevogen received written notice from Nasdaq on September 29, 2026, confirming it regained compliance with the $50 million minimum market value of listed securities requirement for continued listing on the Nasdaq Global Market. With this and a prior September 9, 2026 notice on publicly held shares, both Nasdaq compliance matters are now closed, removing the listing deficiency concerns the company had previously disclosed.
Nasdaq notice dated September 29, 2026 confirmed compliance with the $50 million minimum market value of listed securities requirement (Rule 5450(b)(2)(A))
Earlier notice dated September 9, 2026 confirmed compliance with the minimum market value of publicly held shares requirement (Rules 5450(b)(2)(C) and 5450(b)(3)(C))
Company issued a press release on September 30, 2026, furnished as Exhibit 99.1
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Tevogen Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →